Skip to main content
Erschienen in: PharmacoEconomics 2/2016

01.02.2016 | Current Opinion

Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats

verfasst von: Brendan Collins

Erschienen in: PharmacoEconomics | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

‘Big data’ is the collective name for the increasing capacity of information systems to collect and store large volumes of data, which are often unstructured and time stamped, and to analyse these data by using regression and other statistical techniques. This is a review of the potential applications of big data and health economics, using a SWOT (strengths, weaknesses, opportunities, threats) approach. In health economics, large pseudonymized databases, such as the planned care.data programme in the UK, have the potential to increase understanding of how drugs work in the real world, taking into account adherence, co-morbidities, interactions and side effects. This ‘real-world evidence’ has applications in individualized medicine. More routine and larger-scale cost and outcomes data collection will make health economic analyses more disease specific and population specific but may require new skill sets. There is potential for biomonitoring and lifestyle data to inform health economic analyses and public health policy.
Literatur
1.
Zurück zum Zitat Boyd D, Crawford K. Critical questions for big data: provocations for a cultural, technological, and scholarly phenomenon. Inf Commun Soc. 2012;15(5):662–79.CrossRef Boyd D, Crawford K. Critical questions for big data: provocations for a cultural, technological, and scholarly phenomenon. Inf Commun Soc. 2012;15(5):662–79.CrossRef
4.
5.
Zurück zum Zitat Menius JA Jr, Rousculp MD. Growth in health care data causing an evolution in the pharmaceutical industry. NC Med J. 2014;75(3):188–90. Menius JA Jr, Rousculp MD. Growth in health care data causing an evolution in the pharmaceutical industry. NC Med J. 2014;75(3):188–90.
9.
Zurück zum Zitat Hawkes N. Patient coding and the ratings game. BMJ. 2010;340:950–2.CrossRef Hawkes N. Patient coding and the ratings game. BMJ. 2010;340:950–2.CrossRef
10.
Zurück zum Zitat El Emam K, Arbuckle L, Koru G, Eze B, Gaudette L, Neri E, Rose S, Howard J, Gluck J. De-identification methods for open health data: the case of the Heritage Health Prize claims dataset. J Med Internet Res. 2012;14(1):e33. doi:10.2196/jmir.2001. El Emam K, Arbuckle L, Koru G, Eze B, Gaudette L, Neri E, Rose S, Howard J, Gluck J. De-identification methods for open health data: the case of the Heritage Health Prize claims dataset. J Med Internet Res. 2012;14(1):e33. doi:10.​2196/​jmir.​2001.
11.
Zurück zum Zitat Ayres I. Super crunchers: how anything can be predicted. London: John Murray; 2007. Ayres I. Super crunchers: how anything can be predicted. London: John Murray; 2007.
12.
Zurück zum Zitat Lazer DM, Kennedy R, King G, Vespignani A. The parable of Google flu: traps in big data analysis. Science. 2014;343(6176):1203.CrossRefPubMed Lazer DM, Kennedy R, King G, Vespignani A. The parable of Google flu: traps in big data analysis. Science. 2014;343(6176):1203.CrossRefPubMed
13.
Zurück zum Zitat Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR. Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis. Bone Jt J. 2013;95(1):115–21.CrossRef Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR. Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis. Bone Jt J. 2013;95(1):115–21.CrossRef
14.
Zurück zum Zitat Baicker K, Taubman SL, Allen HL, Bernstein M, Gruber JH, Newhouse JP, Finkelstein AN. The Oregon experiment—effects of medicaid on clinical outcomes. N Engl J Med. 2013;368(18):1713–22.PubMedCentralCrossRefPubMed Baicker K, Taubman SL, Allen HL, Bernstein M, Gruber JH, Newhouse JP, Finkelstein AN. The Oregon experiment—effects of medicaid on clinical outcomes. N Engl J Med. 2013;368(18):1713–22.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Chui M, Löffler M, Roberts R. The internet of things. McKinsey Q. 2010;2:1–9. Chui M, Löffler M, Roberts R. The internet of things. McKinsey Q. 2010;2:1–9.
17.
Zurück zum Zitat Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796.PubMedCentralCrossRefPubMed Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Staa TPV, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, Delaney B, Smeeth L. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.PubMedCentralCrossRefPubMed Staa TPV, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, Delaney B, Smeeth L. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Abramson JD, Rosenberg HD, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.CrossRefPubMed Abramson JD, Rosenberg HD, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.CrossRefPubMed
20.
Zurück zum Zitat Cooper A, O’Flynn N. Guidelines: risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ. 2008;336(7655):1246.PubMedCentralCrossRefPubMed Cooper A, O’Flynn N. Guidelines: risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ. 2008;336(7655):1246.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRisk cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34–9.CrossRefPubMed Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRisk cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34–9.CrossRefPubMed
22.
Zurück zum Zitat Brouwer WB, Culyer AJ, Van Exel N, Rutten FF. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38.CrossRefPubMed Brouwer WB, Culyer AJ, Van Exel N, Rutten FF. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38.CrossRefPubMed
23.
Zurück zum Zitat McDonough JE. The road ahead for the Affordable Care Act. N Engl J Med. 2012;367(3):199–201.CrossRefPubMed McDonough JE. The road ahead for the Affordable Care Act. N Engl J Med. 2012;367(3):199–201.CrossRefPubMed
24.
Zurück zum Zitat Payton TM, Claypoole T. Privacy in the age of big data: recognizing threats, defending your rights, and protecting your family. Lanham: Rowman & Littlefield; 2014. Payton TM, Claypoole T. Privacy in the age of big data: recognizing threats, defending your rights, and protecting your family. Lanham: Rowman & Littlefield; 2014.
Metadaten
Titel
Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats
verfasst von
Brendan Collins
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 2/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-015-0306-7

Weitere Artikel der Ausgabe 2/2016

PharmacoEconomics 2/2016 Zur Ausgabe